Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Venetoclax in Combination With Azacitidine and CAG as Induction Therapy in Patients With Refractory/Relapse Acute Myeloid Leukemia

NCT05807347 is registered in ClinicalTrials.gov with Hematology department of the 920th hospital as lead sponsor.

NCT NCT05807347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05807347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Venetoclax in Combination With Azacitidine and CAG as Induction Therapy in Patients With Refractory/Relapse Acute Myeloid Leukemia
Lead sponsor
Hematology department of the 920th hospital
Phase
Phase 2
Overall status
Unknown status
Start date
February 1, 2023
Completion date
February 1, 2026
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory/relapse acute myeloid leukemia